Luke V Selby1,2, Ana Fernandez-Bustamante3, Aslam Ejaz1, Ana Gleisner2, Timothy M Pawlik1, David J Douin4. 1. Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. 2. Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA. 3. Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA. 4. Department of Anesthesiology, University of Colorado School of Medicine, Aurora, CO, USA. david.douin@cuanschutz.edu.
Abstract
BACKGROUND: Surgery is required for cure of most solid tumors, and general anesthesia is required for most cancer surgery. The vast majority of cancer surgery is facilitated by general anesthesia using volatile inhalational agents such as isoflurane and sevoflurane. Only recently have the immunologic and oncologic effect of inhalational agents, and their alternative, propofol-based total intravenous anesthesia (TIVA), come under investigation. METHODS: Between January 2019 and June 2020, English language articles on PubMed were searched for the keywords "Propofol" "TIVA" or "IV anesthesia" and either "cancer surgery" or "surgical oncology." Duplicates were removes, manuscripts classified as either in vitro, animal, translational, or clinical studies, and their results summarized within these categories. RESULTS: In-vitro and translational data suggest that inhalational anesthetics are potent immunosuppressive and tumorigenic agents that promote metastasis, while propofol is anti-inflammatory, anti-tumorigenic, and prevents metastasis development. Clinically there is a recurring association, based largely on retrospective, single institution series, that TIVA is associated with significant improvements in disease-free interval and overall survival in a number of, but not all, solid tumors. The longer the surgery is, the more intense the surgical trauma is, the more aggressive the malignancy is, and the higher likelihood of an association is. DISCUSSION: Prospective randomized trials, coupled with basic science and translational studies, are needed to further define this association.
BACKGROUND: Surgery is required for cure of most solid tumors, and general anesthesia is required for most cancer surgery. The vast majority of cancer surgery is facilitated by general anesthesia using volatile inhalational agents such as isoflurane and sevoflurane. Only recently have the immunologic and oncologic effect of inhalational agents, and their alternative, propofol-based total intravenous anesthesia (TIVA), come under investigation. METHODS: Between January 2019 and June 2020, English language articles on PubMed were searched for the keywords "Propofol" "TIVA" or "IV anesthesia" and either "cancer surgery" or "surgical oncology." Duplicates were removes, manuscripts classified as either in vitro, animal, translational, or clinical studies, and their results summarized within these categories. RESULTS: In-vitro and translational data suggest that inhalational anesthetics are potent immunosuppressive and tumorigenic agents that promote metastasis, while propofol is anti-inflammatory, anti-tumorigenic, and prevents metastasis development. Clinically there is a recurring association, based largely on retrospective, single institution series, that TIVA is associated with significant improvements in disease-free interval and overall survival in a number of, but not all, solid tumors. The longer the surgery is, the more intense the surgical trauma is, the more aggressive the malignancy is, and the higher likelihood of an association is. DISCUSSION: Prospective randomized trials, coupled with basic science and translational studies, are needed to further define this association.
Authors: Jonathan G Hiller; Nicholas J Perry; George Poulogiannis; Bernhard Riedel; Erica K Sloan Journal: Nat Rev Clin Oncol Date: 2017-12-28 Impact factor: 66.675
Authors: Andrea Yap; Maria A Lopez-Olivo; Julia Dubowitz; Jonathan Hiller; Bernhard Riedel Journal: Can J Anaesth Date: 2019-03-04 Impact factor: 5.063
Authors: Hanna Dillekås; Romano Demicheli; Ilaria Ardoino; Svein A H Jensen; Elia Biganzoli; Oddbjørn Straume Journal: Breast Cancer Res Treat Date: 2016-06-15 Impact factor: 4.872